09/22/2021 | Press release | Distributed by Public on 09/22/2021 15:09
|
LEAP THERAPEUTICS, INC.
|
| | |
| | |
Per Share
|
| |
Per Pre-Funded
Warrant |
| |
Total
|
| |||||||||
Public offering price
|
| | | $ | 2.85 | | | | | $ | 2.849 | | | | | $ | 90,051,228 | | |
Underwriting discounts and commissions(1)
|
| | | $ | 0.171 | | | | | $ | 0.171 | | | | | $ | 5,403,074 | | |
Proceeds to us, before expenses
|
| | | $ | 2.679 | | | | | $ | 2.678 | | | | | $ | 84,648,154 | | |
| PIPER SANDLER | | |
RAYMOND JAMES
|
| |
MIZUHO SECURITIES
|
|
| Prospectus Supplement | | | | | | | |
|
About This Prospectus Supplement
|
| | | | S-1 | | |
|
Special Note Regarding Forward-Looking Statements
|
| | | | S-2 | | |
|
Prospectus Supplement Summary
|
| | | | S-3 | | |
|
The Offering
|
| | | | S-5 | | |
|
Risk Factors
|
| | | | S-7 | | |
|
Use Of Proceeds
|
| | | | S-9 | | |
|
Dividend Policy
|
| | | | S-10 | | |
|
Dilution
|
| | | | S-11 | | |
|
Description of Pre-Funded Warrants
|
| | | | S-13 | | |
|
Underwriting
|
| | | | S-14 | | |
|
Legal Matters
|
| | | | S-20 | | |
|
Experts
|
| | | | S-20 | | |
|
Where You Can Find More Information
|
| | | | S-20 | | |
|
Incorporation of Certain Information by Reference
|
| | | | S-20 | | |
| Prospectus | | | | | | | |
|
About This Prospectus
|
| | | | 1 | | |
|
Leap Therapeutics, Inc.
|
| | | | 2 | | |
|
Special Note Regarding Forward-Looking Statements
|
| | | | 5 | | |
|
Risk Factors
|
| | | | 6 | | |
|
Use of Proceeds
|
| | | | 6 | | |
|
Description of Capital Stock
|
| | | | 7 | | |
|
Description of Warrants
|
| | | | 11 | | |
|
Description of Debt Securities
|
| | | | 13 | | |
|
Description of Rights
|
| | | | 19 | | |
|
Description of Units
|
| | | | 21 | | |
|
Plan of Distribution
|
| | | | 21 | | |
|
Legal Matters
|
| | | | 24 | | |
|
Experts
|
| | | | 24 | | |
|
Where You Can Find More Information
|
| | | | 24 | | |
|
Incorporation of Certain Information by Reference
|
| | | | 24 | | |
|
Disclosure of Commission's Position on Indemnification for Securities Act Liability
|
| | | | 25 | | |
|
Public offering price per share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | | | | | | | $ | 2.85 | | |
|
Net tangible book value per share as of June 30, 2021
|
| | | $ | 0.50 | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering
|
| | | $ | 0.88 | | | | | | | | |
|
Net tangible book value per share as of June 30, 2021, as adjusted after giving effect to this
offering |
| | | | | | | | | $ | 1.38 | | |
|
Dilution per share to new investors purchasing shares in this offering
|
| | | | | | | | | $ | 1.47 | | |
Underwriter
|
| |
Number of Firm
Shares and/or Pre-Funded Warrants |
| |
Economic Split
|
| ||||||
Piper Sandler & Co.
|
| | | | 18,170,000 | | | | | | 57.50% | | |
Raymond James & Associates, Inc.
|
| | | | 7,110,000 | | | | | | 22.50% | | |
Mizuho Securities USA LLC
|
| | | | 3,160,000 | | | | | | 10.00% | | |
Robert W. Baird & Co. Incorporated
|
| | | | 3,160,000 | | | | | | 10.00% | | |
TOTAL
|
| | | | 31,600,000 | | | | |
|
100.00%
|
| |
| | |
Per Share
|
| |
Per
Pre-Funded Warrant |
| |
Total Without
Exercise of Over-Allotment Options |
| |
Total With Full
Exercise of Over-Allotment Options |
| ||||||||||||
Public offering price
|
| | | $ | 2.85 | | | | | $ | 2.849 | | | | | $ | 90,051,228 | | | | | $ | 103,560,228 | | |
Underwriting discounts and commissions
|
| | | $ | 0.171 | | | | | $ | 0.171 | | | | | $ | 5,403,074 | | | | | $ | 6,213,614 | | |
Proceeds, before expenses to us
|
| | | $ | 2.679 | | | | | $ | 2.678 | | | | | $ | 84,648,154 | | | | | $ | 97,346,614 | | |
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
LEAP THERAPEUTICS, INC
|
| | | | 2 | | |
|
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | 5 | | |
|
RISK FACTORS
|
| | | | 6 | | |
|
USE OF PROCEEDS
|
| | | | 6 | | |
|
DESCRIPTION OF CAPITAL STOCK
|
| | | | 7 | | |
|
DESCRIPTION OF WARRANTS
|
| | | | 11 | | |
|
DESCRIPTION OF DEBT SECURITIES
|
| | | | 13 | | |
|
DESCRIPTION OF RIGHTS
|
| | | | 19 | | |
|
DESCRIPTION OF UNITS
|
| | | | 21 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 21 | | |
|
LEGAL MATTERS
|
| | | | 24 | | |
|
EXPERTS
|
| | | | 24 | | |
|
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 24 | | |
|
INFORMATION INCORPORATED BY REFERENCE
|
| | | | 24 | | |
|
DISCLOSURE OF COMMISSION'S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY
|
| | | | 25 | | |